NDC 0074-2042

Skyrizi

Risankizumab-rzaa

Skyrizi is a Kit in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is .

Product ID0074-2042_05c4dbfd-4d63-4c5f-950b-cca935a753c3
NDC0074-2042
Product TypeHuman Prescription Drug
Proprietary NameSkyrizi
Generic NameRisankizumab-rzaa
Dosage FormKit
Marketing Start Date2019-04-23
Marketing End Date2023-01-31
Marketing CategoryBLA / BLA
Application NumberBLA761105
Labeler NameAbbVie Inc.
Active Ingredient Strength0
NDC Exclude FlagN

Packaging

NDC 0074-2042-02

1 KIT in 1 CARTON (0074-2042-02) * .83 mL in 1 SYRINGE * 1 mL in 1 PACKET
Marketing Start Date2019-04-23
Marketing End Date2023-01-31
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0074-2042-02 [00074204202]

Skyrizi KIT
Marketing CategoryBLA
Application NumberBLA761105
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2019-04-23

NDC 0074-2042-71 [00074204271]

Skyrizi KIT
Marketing CategoryBLA
Application NumberBLA761105
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-04-23

Drug Details

OpenFDA Data

SPL SET ID:7148c8eb-b39e-e20a-6494-a6df82392858
Manufacturer

NDC Crossover Matching brand name "Skyrizi" or generic name "Risankizumab-rzaa"

NDCBrand NameGeneric Name
0074-1050Skyrizirisankizumab-rzaa
0074-1065SkyriziRisankizumab-rzaa
0074-1070SkyriziRisankizumab-rzaa
0074-2042SkyriziRisankizumab-rzaa
0074-2100Skyrizirisankizumab-rzaa

Trademark Results [Skyrizi]

Mark Image

Registration | Serial
Company
Trademark
Application Date
SKYRIZI
SKYRIZI
87320935 5857879 Live/Registered
AbbVie Biotechnology Ltd.
2017-02-01

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.